Adage Capital Partners
FBRX icon

Adage Capital Partners’s Forte Biosciences FBRX Stock Holding History

Adage Capital Partners’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9M Sell
700,000
-250,000
-26% -$5.93M 0.02% 600
2026
Q1 		$24.6M Buy
950,000
+616,667
+185% +$17.8M 0.04% 417
2025
Q4 		$9.09M Hold
333,333
– – 0.01% 690
2025
Q3 		$5M Hold
333,333
– – 0.01% 732
2025
Q2 		$4.31M Buy
+333,333
New +$2.87M 0.01% 720

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Adage Capital Partners's FBRX Position: Q2 2026 in Review

Adage Capital Partners reduced its Forte Biosciences (FBRX) stake by 26% in Q2 2026, selling an estimated $5.93M and leaving 700,000 shares worth $14.9M. The position accounts for 0.02% of the portfolio, ranked #600.

Adage Capital Partners first reported a position in FBRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $24.6M in Q1 2026. 56 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Adage Capital Partners held 700,000 shares of Forte Biosciences worth $14.9M as of Q2 2026.
  • Adage Capital Partners sold 250,000 Forte Biosciences shares in Q2 2026, an estimated $5.93M.
  • Forte Biosciences made up 0.02% of Adage Capital Partners's portfolio in Q2 2026, its #600 holding.
  • Adage Capital Partners first reported a position in Forte Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Adage Capital Partners's Forte Biosciences position peaked at $24.6M in Q1 2026.
  • 56 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.